Get the Stockscreener App
8.37
0.48%
0.04
Pre-market:
8.73
0.36
+4.30%
Xencor Inc stock is traded at $8.37, with a volume of 870.09K.
It is up +0.48% in the last 24 hours and up +5.28% over the past month.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
See More
Previous Close:
$8.33
Open:
$8.3
24h Volume:
870.09K
Relative Volume:
1.21
Market Cap:
$596.97M
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-2.8962
EPS:
-2.89
Net Cash Flow:
$23.50M
1W Performance:
+3.98%
1M Performance:
+5.28%
6M Performance:
-40.85%
1Y Performance:
-49.67%
1-Day Range:
$8.0538
$8.54
1-Week Range:
$7.8301
$8.69
52-Week Range:
$6.92
$27.24
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
8.37 | 609.81M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Does Xencor Inc. have declining or rising EPSJuly 2025 Sentiment & Safe Entry Trade Signal Reports - khodrobank.com
Xencor at Cantor Conference: Strategic Advances in Immunology - Investing.com
Will Xencor Inc. announce a stock splitQuarterly Trade Report & Consistent Profit Trading Strategies - khodrobank.com
Is Xencor Inc. a candidate for recovery playWeekly Stock Recap & High Return Stock Watch Alerts - Newser
How to build a dashboard for Xencor Inc. stockForecast Cut & High Win Rate Trade Alerts - Newser
Real time scanner hits for Xencor Inc. explainedMarket Performance Report & Technical Pattern Recognition Alerts - Newser
Xencor Inc. stock trend outlook and recovery pathJuly 2025 Summary & Free Technical Confirmation Trade Alerts - Newser
Evaluating Xencor Inc. with trendline analysisQuarterly Earnings Summary & Fast Gain Stock Trading Tips - Newser
Earnings visualization tools for Xencor Inc.Quarterly Market Review & Smart Allocation Stock Tips - Newser
Xencor at Wells Fargo Conference: Strategic Advances in Biotech By Investing.com - Investing.com Canada
Xencor at Wells Fargo Conference: Strategic Advances in Biotech - Investing.com
What earnings revisions data tells us about Xencor Inc.2025 Trade Ideas & Accurate Buy Signal Notifications - Newser
Xencor Shares Fall After BofA Securities Downgrade - MarketScreener
Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts - Seeking Alpha
Sector Update: Health Care - MarketScreener
B of A Securities Downgrades Xencor to Neutral with $12 PT. - AInvest
Intraday pattern recognizer results for Xencor Inc.Portfolio Update Summary & Risk Managed Trade Strategies - Newser
BofA Securities Downgrades Xencor to Neutral From Buy - MarketScreener
Xencor Inc. stock outlook for YEARInsider Buying & Verified Entry Point Detection - Newser
Xencor Inc. stock trendline breakdownEarnings Growth Report & Stepwise Swing Trade Plans - Newser
News impact scoring models applied to Xencor Inc.July 2025 Retail & Technical Pattern Alert System - Newser
How to build a custom watchlist for Xencor Inc.Inflation Watch & Expert Approved Trade Ideas - Newser
Is Xencor Inc. reversing from oversold territoryGap Down & Weekly Setup with High ROI Potential - Newser
Published on: 2025-09-03 03:15:31 - Newser
Is it time to cut losses on Xencor Inc.Portfolio Update Report & Verified Chart Pattern Signals - Newser
Automated trading signals detected on Xencor Inc.Market Performance Summary & Low Drawdown Trading Techniques - Newser
Will earnings trigger a reversal in Xencor Inc.Weekly Risk Summary & Reliable Intraday Trade Alerts - Newser
Is Xencor Inc. stock ready for a breakoutMarket Movers & Safe Entry Trade Reports - Newser
Advanced analytics toolkit walkthrough for Xencor Inc.Weekly Gains Report & Verified Swing Trading Watchlist - Newser
Real time social sentiment graph for Xencor Inc.Weekly Trade Report & Weekly High Potential Stock Alerts - Newser
Using Ichimoku Cloud for Xencor Inc. technicals2025 Market Trends & Long Hold Capital Preservation Plans - Newser
Full technical analysis of Xencor Inc. stockWeekly Loss Report & Free Growth Oriented Trading Recommendations - Newser
Is Xencor Inc. forming a bottoming baseJuly 2025 EndofMonth & Trade Opportunity Analysis Reports - Newser
Will Xencor Inc. stock recover after earnings2025 Winners & Losers & Safe Capital Growth Tips - khodrobank.com
Can Xencor Inc. benefit from deglobalizationProduct Launch & Technical Pattern Alert System - khodrobank.com
Key resistance and support levels for Xencor Inc.Portfolio Value Report & Free Safe Entry Trade Signal Reports - Newser
Reversal Traders Monitor Xencor Inc. for Entry2025 Top Gainers & Growth Focused Investment Plans - beatles.ru
Trend analysis for Xencor Inc. this weekWeekly Profit Summary & Community Verified Watchlist Alerts - Newser
Multi asset correlation models including Xencor Inc.Earnings Growth Summary & Growth-Oriented Investment Plans - Newser
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xencor Inc Stock (XNCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GUSTAFSON KURT A | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
20,183 |
| GORMAN KEVIN CHARLES | Director |
Jun 16 '25 |
Sale |
9.22 |
3,173 |
29,255 |
18,905 |
| Feigal Ellen | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
19,183 |
| RANIERI RICHARD J | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
19,183 |
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):